# Kim N.

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kim-n/

## Facts

| Field | Value |
| --- | --- |
| Citations | 52,262 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 83 |
| i10-index | 250 |
| Last Known Institution | BC Cancer Agency |
| OpenAlex ID | https://openalex.org/A5005231494 |
| ORCID iD | 0000-0002-3782-7226 |
| Works | 853 |

## Researcher papers

Showing 12 of 18.

- [Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer](https://scholariq.org/papers/docetaxel-plus-prednisone-or-mitoxantrone-plus-prednisone-for-advanced-prostate/)
- [Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy](https://scholariq.org/papers/increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy/)
- [Abiraterone and Increased Survival in Metastatic Prostate Cancer](https://scholariq.org/papers/abiraterone-and-increased-survival-in-metastatic-prostate-cancer/)
- [Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer/)
- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)
- [Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/abiraterone-plus-prednisone-in-metastatic-castration-sensitive-prostate-cancer/)
- [Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study](https://scholariq.org/papers/prognostic-factors-for-overall-survival-in-patients-with-metastatic-renal-cell/)
- [Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3](https://scholariq.org/papers/trial-design-and-objectives-for-castration-resistant-prostate-cancer-updated/)
- [Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer](https://scholariq.org/papers/enzalutamide-with-standard-first-line-therapy-in-metastatic-prostate-cancer/)
- [Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/apalutamide-for-metastatic-castration-sensitive-prostate-cancer/)
- [Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/abiraterone-acetate-plus-prednisone-in-patients-with-newly-diagnosed-high-risk/)
- [Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/survival-with-olaparib-in-metastatic-castration-resistant-prostate-cancer/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)

## Researcher university

- [BC Cancer Agency](https://scholariq.org/institutions/bc-cancer-agency/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.